Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers

Conclusions The proton pump inhibitor omeprazole did not have a significant influence on the PK behavior of fluzoparib, and its safety profile was good upon co-administration with omeprazole. (NCT04108676, 30 September 2019)

http://link.springer.com/10.1007/s10637-020-01034-w

Source: Investigational New Drugs - January 9, 2021 Category: Drugs & Pharmacology Source Type: research